Although our results support the hypothesis that CD133 expressing cells present within the bulk human endometrial tumor cell population have enhanced tumor initiating capacity, it is highly unlikely that all tumor initiating cells express CD133 or that all CD133+ cells are tumorigenic. This evidence concerns the gene PROM1 and endometrium neoplasm.